SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB AND VEDOLIZUMAB IN IBD IN CLINICAL REMISSION IS ASSOCIATED WITH A LOWER RATE OF DRUG DISCONTINUATION, DRUG OPTIMIZATION, AND REVERSE-SWITCH: AN INTERNATIONAL MULTICENTER STUDY

Ferdinando D'Amico  1     Giulia Palmieri  1     Arianna Dal Buono  2     Roberto Gabbiadini  2     Alessandro Armuzzi  2     Bénédicte Caron  3     Laurent Peyrin-Biroulet  3     Paula Moreira  4     Fernando Magro  4     Unknown Unknown  5     Tommaso Innocenti  6     Gabriele Dragoni  6     Cristina Bezzio  7     María Chaparro  8     Javier Gisbert  8     María José García  9     Georgios Michalopoulos  10     Nikos Viazis  11     Gerassimos J. Mantzaris  11     Pierre Ellul  12     Silvio Danese  1     Gionata Fiorino  1     Mariangela Allocca  1    
1 IRCCS Hospital San Raffaele and University Vita-Salute San Raffaele, Milan, Italy
2 IRCCS Humanitas Research Hospital, Rozzano, Italy
3 University of Lorraine, Nancy, France
4 Unit of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto, Porto, Portugal
5 Hospital Clínico Universitario de Valencia, Valencia, Spain
6 Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
7 Rho Hospital, ASST Rhodense, Milan, Italy
8 Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM), and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Sp
9 Hospital Universitario Marqués de Valdecilla, IDIVAL, Universidad de Cantabria, Santander, Spain
10 General Hospital of Athens "G. Gennimatas", Athens, Greece
11 ‘Evangelismos-Polykliniki’ GHA, Athens, Greece
12 Mater Dei Hospital, Msida, Malta

Topic
IBD

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing